Current antiretroviral therapy and its impact on human immunodeficiency virus-related wasting.

Abstract:

:Recent improvements in the management of people living with human immunodeficiency virus (HIV) disease in the United States have led to remarkable reductions in HIV-related morbidity and mortality. The Centers for Disease Control and Prevention recently reported substantial reductions in acquired immunodeficiency syndrome (AIDS)-related opportunistic infections and conditions, including HIV-related wasting. These achievements followed the introduction of the new class of antiretroviral therapies, the aspartyl protease inhibitors, and their use in combination with nucleoside inhibitors in so-called highly active antiretroviral therapies. In an effort to provide guidance for clinicians in HIV care, the Office of AIDS Research, United States Department of Health and Human Services recently convened a panel of experts to set clinical practice guidelines for the use of antiretroviral therapy in adults and adolescents. This article summarizes the new standard of care for the use of HIV therapies. It also reviews recent data suggesting that combination therapy has altered the natural history of HIV infection and has reduced the incidence of HIV-related nutritional disturbances and wasting.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Sherer R

subject

Has Abstract

pub_date

1998-04-01 00:00:00

pages

92-7

issue

2 Suppl 6

eissn

0093-7754

issn

1532-8708

journal_volume

25

pub_type

杂志文章,评审
  • Introduction to the treatment of lung cancer.

    abstract::Lung cancer represents the leading cause of cancer mortality worldwide. Its incidence has declined in men but is increasing in women, assuring that this largely preventable disease will continue to affect millions. In small cell lung cancer, the advent of chemotherapy in the 1970s and continued refinements in the 1980...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Splinter TA

    更新日期:1997-08-01 00:00:00

  • Immune tolerance and transplantation.

    abstract::Successful allogeneic hematopoietic stem cell transplantation (HSCT) and solid organ transplantation require development of a degree of immune tolerance against allogeneic antigens. T lymphocytes play a critical role in allograft rejection, graft failure, and graft-versus-host disease (GVHD). T-cell tolerance occurs b...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.10.001

    authors: Alpdogan O,van den Brink MR

    更新日期:2012-12-01 00:00:00

  • Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.

    abstract::Preclinical models in vitro and in vivo have shown that tumor hypoxia alters the malignant cell phenotype, selecting for p53 mutations, stimulating angiogenesis and metastasis, and markedly reducing the efficacy of both radiotherapy and chemotherapy. Similarly, clinical studies measuring pretreatment tumor oxygen stat...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.31531

    authors: Gandara DR,Lara PN Jr,Goldberg Z,Le QT,Mack PC,Lau DH,Gumerlock PH

    更新日期:2002-02-01 00:00:00

  • Training and mentoring surgeons in lymphatic mapping.

    abstract::Intraoperative lymphatic mapping and selective lymphadenectomy for solid malignancies is a novel technique, having been introduced into surgical practice in the last 12 years. Dissemination of this technique among surgeons has followed a course similar to that found with the introduction of new laparoscopic techniques...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.03.005

    authors: Wilke LG

    更新日期:2004-06-01 00:00:00

  • The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.

    abstract::Preclinical studies with zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ) have shown its potential in malignant bone disease. Clinical studies in the treatment of hypercalcemia of malignancy have been completed, as have phase I and II trials in patients with cancer and pre-existing bone metast...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.1016/s0093-7754(01)90260-x

    authors: Coleman RE,Seaman JJ

    更新日期:2001-04-01 00:00:00

  • New targeted therapies in breast cancer.

    abstract::Targeted therapy for breast cancer has existed since 1986, when Beatson published his observations on oophorectomy. In the past 5 years monoclonal antibodies and tyrosine kinase inhibitors have been evaluated in phase I and II clinical trials of breast cancer. Trastuzumab (Herceptin; Genentech, Inc, South San Francisc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.02.018

    authors: Kaklamani V,O'Regan RM

    更新日期:2004-04-01 00:00:00

  • Immunotherapeutic strategies for high-risk bladder cancer.

    abstract::Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-g...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.12.004

    authors: Sharma P,Old LJ,Allison JP

    更新日期:2007-04-01 00:00:00

  • Chemotherapeutic approaches to advanced breast cancer.

    abstract::Choices of treatment for patients with estrogen receptor (ER) positive metastatic breast cancer refractory to first-line endocrine therapies include progestins, antiadrenal drugs, and androgens. These treatments should be administered sequentially to achieve maximum palliation of the disease. For ER positive patients ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Buzdar AU

    更新日期:1988-06-01 00:00:00

  • Overview of phase I trials of multitargeted antifolate (MTA, LY231514).

    abstract::Multitargeted antifolate (MTA, LY231514) is a novel antifolate antimetabolite, with antitumor activity via inhibition of thymidylate synthase, glycinamide formyl transferase, and dihydrofolate reductase. Three dosing schedules have been investigated in the phase I setting: daily x5 every 21 days, weekly x4 every 42 da...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Rinaldi DA

    更新日期:1999-04-01 00:00:00

  • Hematopoietic growth factors in AIDS.

    abstract::Three hematopoietic growth factors, erythropoietin, GM-CSF, and G-CSF, have all been evaluated in the context of HIV infection. Recombinant human Epo is currently licensed for therapy of anemia related to zidovudine and is well tolerated in this patient population. Although myelosuppression can clearly be overcome usi...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Groopman JE,Feder D

    更新日期:1992-08-01 00:00:00

  • Treatment of advanced non-small cell lung cancer (NSCLC): the "Umbria" cooperative study.

    abstract::One hundred fifty-six patients with metastatic or locally advanced non-small cell lung cancer (NSCLC) were randomized to 3-week cycles of treatment with either: (A) cisplatin (120 mg/m2 on day 1); (B) cisplatin (120 mg/m2 on day 1) plus etoposide (VP-16) (100 mg/m2 on days 1-3; and (C) the cisplatin plus etoposide (VP...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Crinó L,Darwish S,Corgna E,Meacci ML,Di Costanzo F,Buzzi F,Fornari G,Santi F,Ballatori E,Luccioli L

    更新日期:1988-12-01 00:00:00

  • Antiestrogen therapy of breast cancer.

    abstract::Studies in vitro and in animal models have helped define the mechanism of action of antiestrogens and the differences in the physical properties of the various antiestrogens. Tamoxifen is the most widely studied antiestrogen. A review of 45 separate studies has shown a response rate to tamoxifen in advanced breast can...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Lippman ME

    更新日期:1983-12-01 00:00:00

  • Recently identified peptides involved in the regulation of body weight.

    abstract::The application of molecular and genetic techniques to the study of body weight regulation have produced exciting new insights into the physiological systems governing energy expenditure, appetite, and metabolic signaling. A number of new peptides have been identified that play important roles in these regulatory syst...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bessesen DH,Faggioni R

    更新日期:1998-04-01 00:00:00

  • Single-agent oral etoposide for elderly small cell lung cancer patients.

    abstract::Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rate...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Carney DN,Grogan L,Smit EF,Harford P,Berendsen HH,Postmus PE

    更新日期:1990-02-01 00:00:00

  • Richter syndrome: pathogenesis and management.

    abstract::Richter syndrome (RS) is the development of an aggressive lymphoma in patients with a previous or concomitant diagnosis of chronic lymphocytic leukemia (CLL). The incidence rate RS is ~0.5% per year of observation. Two biomarkers (NOTCH1 mutations and subset 8 configuration of the B-cell receptor) may help identifying...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.02.012

    authors: Rossi D,Gaidano G

    更新日期:2016-04-01 00:00:00

  • Prognostic factors in renal carcinoma.

    abstract::Identification of tumor-, patient-, or treatment-related prognostic factors in renal carcinoma (RC) would allow the most appropriate application of current and future therapy to patients with this poorly responsive malignancy. Stage, including degree of lymph node and venous involvement, and grade remain the most powe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Rini BI,Vogelzang NJ

    更新日期:2000-04-01 00:00:00

  • Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors.

    abstract::Improving local tumor control is a goal of modern radiotherapy that will directly impact a majority of cancer patients. Numerous attempts to develop radiosensitizing agents have, however, met with limited clinical success. Recent advances in gene therapeutic approaches have allowed researchers to combine gene therapy ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Advani SJ,Chmura SJ,Weichselbaum RR

    更新日期:1997-12-01 00:00:00

  • Metabolism and action of fludarabine phosphate.

    abstract::Fludara I.V. (fludarabine phosphate) (9-beta-D-arabinosyl-2-fluoroadenine, F-ara-A) is an adenine nucleoside analogue resistant to adenosine deaminase that shows promising therapeutic activity in the clinical treatment of lymphocytic hematologic malignancies. F-ara-A is transported into cells, where it is converted to...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Plunkett W,Huang P,Gandhi V

    更新日期:1990-10-01 00:00:00

  • Salvage chemotherapy in recurrent or refractory squamous cell cancer of the uterine cervix.

    abstract::Squamous cell cancer of the cervix is a relatively drug-resistant tumor. Therefore, chemotherapy is predominantly reserved for cervical cancer patients with recurrent or refractory disease following surgery and/or radiation therapy or for patients who present with far advanced, incurable disease. Objective responses t...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Alberts DS,Garcia DJ

    更新日期:1994-08-01 00:00:00

  • The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.

    abstract::The Wayne State University Waldenstrom's Macroglobulinemia xenograft model in mice with severe combined immune deficiency (WSU-WM-SCID) is the only preclinical animal model available for this disease. It is based on a permanent, EBV- IgMlambda cell line (WSU-WM) established from a patient with a 10-year history of Wal...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/sonc.2003.50043

    authors: Al-Katib AM,Mensah-Osman E,Aboukameel A,Mohammad R

    更新日期:2003-04-01 00:00:00

  • Gemcitabine/carboplatin in advanced urothelial cancer.

    abstract::Transitional cell carcinoma of the urothelium is a highly chemosensitive tumor. Combination chemotherapy can provide both palliation and a modest survival advantage in patients with advanced disease. As shown in a recent phase III trial, the new gold standard should be considered gemcitabine/cisplatin, although toxici...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2001.22537

    authors: Carles J,Nogué M

    更新日期:2001-06-01 00:00:00

  • Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer.

    abstract::A phase I/II study was conducted to determine the response rate and the toxicity of escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin with granulocyte colony-stimulating factor support in patients with untreated advanced head and neck carcinoma. Twenty-eight patients wi...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Hitt R,Paz-Ares L,Hidalgo M,Colomer R,Brandariz A,Peña M,Alvarez-Vicent J,Hornedo J,Cortés-Funes H

    更新日期:1997-12-01 00:00:00

  • How are bisphosphonates used today in breast cancer clinical practice?

    abstract::In the United States there are approximately 100,000 women living with metastatic breast cancer. Bone is the most common site of breast cancer metastases and it is estimated that up to 85% of patients dying from this disease have developed osseous involvement. Skeletal metastases are often associated with dangerous an...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2001.25445

    authors: Van Poznak C

    更新日期:2001-08-01 00:00:00

  • Paclitaxel pharmacokinetics and pharmacodynamics.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the pla...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Kearns CM,Gianni L,Egorin MJ

    更新日期:1995-06-01 00:00:00

  • Diagnosis and treatment of metastatic disease to the liver.

    abstract::A number of cancers present with synchronous or metachronous hepatic metastases. Historically, many of these patients were considered unresectable and were treated with either systemic chemotherapy or supportive care. Today, a variety of options exist for the management of hepatic metastases. Newer agents for systemic...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.12.004

    authors: Arciero CA,Sigurdson ER

    更新日期:2008-04-01 00:00:00

  • Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hydroxyurea.

    abstract::Preclinical studies have indicated that hydroxyurea leads to enhancement of 5-fluorouracil (5-FU) activity when given after 5-FU. This is presumably due to hydroxyurea's actions resulting in maintaining low levels of deoxyuridine monophosphate pools. The combination of hydroxyurea and 5-FU has been tested in several i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Muggia FM,Moran RG

    更新日期:1992-06-01 00:00:00

  • Management of side effects in patients with recurrent ovarian cancer.

    abstract::As with many other aspects of health care delivery in the United States, the entrenchment of managed care practices has significantly affected the management of patients with advanced ovarian cancer. Nurses continue to play a vital role in the delivery of health care in this venue, serving as the primary conduit betwe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Larrison EH

    更新日期:1999-02-01 00:00:00

  • Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.

    abstract::The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2017.08.004

    authors: Capoluongo E,Ellison G,López-Guerrero JA,Penault-Llorca F,Ligtenberg MJL,Banerjee S,Singer C,Friedman E,Markiefka B,Schirmacher P,Büttner R,van Asperen CJ,Ray-Coquard I,Endris V,Kamel-Reid S,Percival N,Bryce J,Röthlisbe

    更新日期:2017-06-01 00:00:00

  • Profiling the safety and tolerability of bisphosphonates.

    abstract::Because patients with metastatic bone disease suffer a significant burden from their illness and from anticancer treatments, it is therefore important to minimize the side effects of bisphosphonates. The intravenous bisphosphonates, zoledronic acid and pamidronate, have tolerability issues that include a flu-like synd...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.07.030

    authors: Body JJ,Diel I,Bell R

    更新日期:2004-10-01 00:00:00

  • Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist.

    abstract::The epidemiologic studies relevant to the hypothesis that exposure to tamoxifen is associated with risk of cancer of the endometrium and perhaps other organs are described, summarized, and evaluated. One large body of data comes from the randomized trials of tamoxifen as a therapeutic agent against established breast ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: MacMahon B

    更新日期:1997-02-01 00:00:00